Targeting Chemoresistance in Advanced Bladder Cancers with a Novel Adjuvant Strategy

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Advanced bladder cancer (BC) presents significant therapeutic challenges due to rapid progression and resistance to standard chemotherapy like Gemcitabine.
• High-grade tumors (>T2a) constitute a substantial portion of BC diagnoses, often exhibiting poor response to current treatments.
• Existing adjuvant therapies offer limited efficacy, necessitating the exploration of novel treatment strategies.

Purpose of the Study:

• To evaluate the therapeutic potential of a novel Ursolic Acid derivative, UA4, against both Gemcitabine-sensitive and Gemcitabine-resistant human bladder cancer cell lines.
• To investigate the efficacy of UA4, alone and in combination with Gemcitabine, in preclinical models of bladder cancer.
• To elucidate the mechanism of action underlying UA4's anti-cancer effects.

Main Methods:

• In vitro assessment of UA4's cytotoxicity on human bladder cancer cell lines (5637 and T24), including Gemcitabine-resistant variants.
• Evaluation of synergistic effects of UA4 combined with Gemcitabine using different administration sequences.
• In vivo efficacy studies using athymic mice bearing human bladder cancer xenografts, assessing tumor growth inhibition and toxicity.
• Mechanistic studies involving analysis of apoptosis, reactive oxygen species (ROS) production, mitochondrial function, and cell cycle progression.

Main Results:

• UA4 demonstrated potent in vitro cytotoxicity against both Gemcitabine-sensitive and resistant bladder cancer cells at low micromolar concentrations.
• Pretreatment with UA4 followed by Gemcitabine exhibited synergistic killing effects, significantly enhancing efficacy compared to sequential administration or single agents.
• Oral administration of UA4 effectively inhibited tumor growth in vivo without observable systemic toxicity in mice.
• Mechanistic investigations revealed that UA4 induces cytotoxicity through ROS-mediated mitochondrial dysfunction and cell cycle arrest, triggering cytotoxic autophagy.

Conclusions:

• UA4 exhibits significant anti-cancer activity against advanced and Gemcitabine-resistant bladder cancer, both in vitro and in vivo.
• The combination of UA4 and Gemcitabine offers a promising synergistic therapeutic strategy for bladder cancer treatment.
• UA4 represents a potential non-toxic, orally available therapeutic agent for high-grade bladder cancer, warranting further clinical investigation.